Cellectis S.A. (CLLS) has released an update.
Cellectis S.A., a clinical-stage biotechnology company, has completed a substantial $140M equity investment by AstraZeneca, following approvals and the fulfillment of all closing conditions. This investment resulted in AstraZeneca acquiring approximately 44% of Cellectis’ share capital and 30% of voting rights, strengthening the partnership between the two companies. Additionally, as part of the investment terms, two new members have been appointed to Cellectis’ board of directors.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
